Erectile Dysfunction Market to Surpass 4.73 Billion by 2030 Drives Due to the Growing Awareness and Treatment Options
SkyQuest projects that the erectile dysfunction market will attain a USD 4.73 billion value by 2030, with a CAGR of 8.5% over the forecast period (2023-2030). The global erectile dysfunction market is expanding due to increased awareness about the condition and the availability of various treatment options. Men are seeking medical assistance for this sensitive issue, leading to a higher demand for medications, therapies, and devices designed to address erectile dysfunction.
Westford USA, Aug. 15, 2023 (GLOBE NEWSWIRE) — According to SkyQuest, the ageing population is a significant driver of the erectile dysfunction market. As men age, the likelihood of experiencing erectile dysfunction increases. Additionally, unhealthy lifestyle factors such as obesity, smoking, and sedentary habits contribute to the condition’s prevalence, further propelling the market growth.
Browse In-Depth TOC On the “Erectile Dysfunction Market”
- Pages – 165
- Tables – 39
- Figures – 73
Get a sample copy of this report:
Technological advancements in the field of erectile dysfunction treatment are driving market expansion. Innovations like shockwave therapy, penile implants, and personalized treatment approaches offer more effective and minimally invasive solutions. These advancements cater to the growing demand for treatments with satisfactory results with fewer side effects, boosting the market’s overall growth trajectory.
Prominent Players in The Erectile Dysfunction Market
- Pfizer Inc.
- Eli Lilly and Company
- Bayer AG
- VIVUS, Inc.
- Dong-A ST Co. Ltd.
- Meda Pharmaceuticals Inc.
- S.K. Chemicals Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Endo International plc
- Futura Medical plc
- Apricus Biosciences, Inc.
- Medtronic plc
- Coloplast Corp.
- Boston Scientific Corporation
- Zephyr Surgical Implants
- Urologix, LLC
- American Medical Systems, Inc.
- Augusta Medical Systems, LLC
- Pos-T-Vac Medical
Browse summary of the report and Complete Table of Contents (ToC):
Cialis Segment is Expected to Grow the Market Due to their Widespread Integration
Cialis stands out as a rapid-growth segment in the global erectile dysfunction market. Its extended duration of action sets it apart, appealing to consumers seeking spontaneity. With increasing adoption and patent expirations, generic versions contribute to market growth, making Cialis a pivotal player in addressing erectile dysfunction.
North America dominates the global erectile dysfunction market due to factors like a high prevalence of the condition, advanced healthcare infrastructure, and rising awareness. Robust research efforts, accessibility to innovative treatments, and changing societal attitudes contribute to North America’s significant share in addressing and treating erectile dysfunction.
Viagra Segment is Expected to Dominate the Market Due to its Escalating Trend of Health-Conscious Snacking
Viagra dominates the global erectile dysfunction market due to its established efficacy and brand recognition. As a widely recognized oral medication, it addresses a broad consumer base. It’s reliable performance and extensive market presence contribute to Viagra’s prominence within the segment.
Regional markets in the Asia-Pacific (APAC) region demonstrate rapid growth in the global erectile dysfunction market. Increasing healthcare awareness, urbanization, and changing lifestyles contribute to the rise in demand for treatments. A large population base and evolving healthcare infrastructure further drive the APAC region’s significant expansion in addressing erectile dysfunction.
A comprehensive analysis of the major players in the erectile dysfunction market has been recently conducted in a report. The report encompasses various aspects, including collaborations, mergers, innovative business policies, and strategies, providing valuable insights into key trends and breakthroughs in the market. Furthermore, the report scrutinizes the market share of the top segments and presents a detailed geographic analysis. Lastly, the report highlights the major players in the industry and their endeavors to develop innovative solutions to cater to the growing demand.
Key Developments in The Erectile Dysfunction Market
- In August 2022,Lupin launched an oral drug named sildenafil for erectile dysfunction in the United States.
- In May 2022, Aspargo Laboratories, Inc. purchased the prescription brand Bandol from the Spanish specialty pharmaceutical company Laboratorios Rubio S.A. Bandol is used to treat patients with ED problems.
Speak to Analyst for your custom requirements:
Key Questions Answered in Erectile Dysfunction Market Report
- What specific growth drivers are projected to impact the market during the forecast period?
- List the top companies in the market and explain how they have achieved their positions of influence.
- In what ways do regional trends and patterns differ within the global market, and how these differences shape the market’s future growth?
Related Reports in SkyQuest’s Library:
Global Biotechnology & Pharmaceutical Services Outsourcing Market
Global Shingles Vaccine Market
Global Bovine Lactoferrin Market
Global Pharmaceutical Manufacturing Market
Global Immune Health Supplements Market
SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.
1 Apache Way, Westford, Massachusetts 01886
USA (+1) 617-230-0741
Email: [email protected]
LinkedIn Facebook Twitter
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.